MVA-NP+M1

BIOLOGICAL6 trials

Sponsors

University of Oxford, Barinthus Biotherapeutics

Conditions

Human VolunteersInfluenza

Early Phase 1

A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1

CompletedNCT03277456

Barinthus BiotherapeuticsHuman Volunteers

Start: 2017-09-18End: 2017-11-02Updated: 2017-11-14

Phase 1

A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults

CompletedNCT00942071

University of OxfordInfluenza

Start: 2008-08-31End: 2012-11-30Updated: 2012-11-29

Phase 2

A Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults

CompletedNCT00993083

University of OxfordInfluenza

Start: 2009-06-30End: 2010-03-31Updated: 2011-08-11

Improved Novel VaccIne CombinaTion InflUenza Study

TerminatedNCT03300362

Barinthus BiotherapeuticsInfluenza

Start: 2017-10-13End: 2018-10-31Updated: 2018-11-23

Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults

TerminatedNCT03880474

Barinthus BiotherapeuticsInfluenza

Start: 2019-03-18End: 2020-01-21Updated: 2021-04-26

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

CompletedNCT03883113

Barinthus BiotherapeuticsInfluenza

Start: 2019-06-03End: 2020-04-17Updated: 2021-03-18

Related Papers

Innate immune molecular landscape following controlled human influenza virus infection.

2025-09-16

Intranasal insulin for the treatment of alcohol use disorder: design and methodology of an alcohol interaction randomized controlled trial.

2025-06-10

Assessment of CD8<sup>+</sup> T-cell mediated immunity in an influenza A(H3N2) human challenge model in Belgium: a single centre, randomised, double-blind phase 2 study.

2024-05-078 citations

Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine

Frontiers in Immunology2022-04-0724 citations

Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial.

2022-03-1630 citations

A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed Ina CTivated infl Uenza vaccine in adult S aged 65 years and above (INVICTUS): a study protocol.

2019-05-2314 citations

Referee report. For: A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed InaCTivated inflUenza vaccine in adultS aged 65 years and above (INVICTUS): a study protocol [version 1; peer review: 1 approved with reservations]

Faculty of 1000 Research Ltd2019-01-01

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.

2012-10-31101 citations

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.

2012-03-22205 citations